Lysosomal pH Modulation for Alzheimer's Protein Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alzheimer's disease is characterized by impaired lysosomal activity, leading to defective neuronal protein clearance and autophagy dysfunction, with existing treatments failing to effectively address the underlying mechanistic underpinnings of the disease.
Innovation Solution
Administering agents or compounds that enhance lysosomal activity, such as β-adrenergic agonists, cAMP agonists, or Ca2+ pump inhibitors, to restore normal lysosomal pH and protease activity, thereby treating Alzheimer's disease by improving lysosomal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Alzheimer's disease treatments are used, then symptomatic relief may be achieved, but the underlying lysosomal dysfunction and protein clearance defects are not effectively addressed
Solution Approach 1:
The patent applies preliminary action by using screening assays to identify compounds that can prevent or correct lysosomal dysfunction before it leads to severe protein aggregation and neuronal damage. The method screens for agents that can restore lysosomal pH and protease activity in advance, addressing the root cause rather than just symptoms.
Solution Approach 2:
The patent uses screening assays as an intermediary tool to identify therapeutic agents. The assay system (cells expressing PS1 mutations, lysosomal pH indicators, protease activity reporters) serves as a mediator to evaluate potential compounds' ability to correct lysosomal dysfunction, bridging the gap between drug discovery and clinical application.
2Productivity
If lysosomal activity is enhanced to restore pH and protease activity, then protein clearance improves, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent creates a universal screening assay system that can evaluate multiple therapeutic candidates simultaneously for their ability to correct various aspects of lysosomal dysfunction (pH, protease activity, protein clearance). This multi-functional assay reduces the need for separate tests for each therapeutic target.
Solution Approach 2:
The patent employs parameter changes by using fluorescent indicators and reporters that change their optical properties in response to lysosomal pH and protease activity levels. These measurable parameter changes enable high-throughput screening of compounds without complex biochemical assays.
3Measurement precision
If compounds are screened to identify those that increase lysosomal pH and protease activity, then therapeutic agents for Alzheimer's disease can be discovered, but the screening process requires sophisticated assay systems
Solution Approach 1:
The patent replaces complex mechanical and biochemical measurement systems with optical detection methods. Fluorescent pH indicators and protease activity reporters allow lysosomal pH and enzyme activity to be measured through fluorescence intensity changes, eliminating the need for invasive sampling and complex biochemical assays.
Solution Approach 2:
The patent uses cell-based models expressing human PS1 mutations as copies of the disease state, allowing screening of therapeutic agents in a controlled in vitro system that replicates the pathological conditions without requiring human patient samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively restores lysosomal pH and protease activity, ameliorating autophagy deficits and protein clearance in Alzheimer's disease, providing a therapeutic approach to address the disease's pathogenic mechanisms.
Implementation Method 1
Administering agents or compounds that enhance lysosomal activity, such as β-adrenergic agonists, cAMP agonists, or Ca2+ pump inhibitors, to restore normal lysosomal pH and protease activity
Data Source
AI summary
Methods for treating Alzheimer's Disease (AD) using modulators of lysosomal activity are described herein. More particularly, methods described herein relate to the use and application of compounds or agents that enhance lysosomal activity for the treatment of AD. In a particular aspect, the method relates to the use and application of compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD. Also described herein are methods and assays for screening to identify compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD.